Safety and tolerability of an immediate-release formulation of the oral direct thrombin inhibitor AZD0837 in the prevention of stroke and systemic embolism in patients with atrial fibrillation

Bertil S. Olsson; Lars H. Rasmussen; Arnljot Tveit; Eva Jensen; Peter Wessman; Seva Panfilov; Karin Wåhlander

doi:10.1160/TH09-07-0509

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 2010; 103(03): 604-612
DOI: 10.1160/TH09-07-0509

Blood Coagulation, Fibrinolysis and Cellular Haemostasis

Schattauer GmbH

Safety and tolerability of an immediate-release formulation of the oral direct thrombin inhibitor AZD0837 in the prevention of stroke and systemic embolism in patients with atrial fibrillation

Autor*innen

Bertil S. Olsson

¹Department of Cardiology, Lund University Hospital, Sweden
Lars H. Rasmussen

²Department of Cardiology, Aalborg Hospital, Aarhus University Hospital, Denmark
Arnljot Tveit

³Department of Internal Medicine, Asker and Baerum Hospital, Norway
Eva Jensen

⁴AstraZeneca R&D, Mölndal, Sweden
Peter Wessman

⁴AstraZeneca R&D, Mölndal, Sweden
Seva Panfilov

⁴AstraZeneca R&D, Mölndal, Sweden
Karin Wåhlander

⁴AstraZeneca R&D, Mölndal, Sweden

Abstract

Summary

AZD0837 is an investigational oral anticoagulant which is converted to the active form, AR-H067637, a selective direct thrombin inhibitor. The present study, a multicentre, randomised, parallel-group, dose-guiding study, assessed the safety and tolerability of an immediate-release formulation of AZD0837 compared with dose-adjusted warfarin in the prevention of stroke and systemic embolic events in atrial fibrillation (AF) patients. Two hundred fifty AF patients with at least one additional risk factor for stroke were randomised to receive either immediate-release AZD0837 (150 mg twice daily [bid] or 350 mg bid, blinded treatment) or dose-adjusted warfarin (international normalised ratio 2.0–3.0, open treatment) for three months. The safety and tolerability of 150 mg bid AZD0837 appeared to be as good as that of warfarin. Total bleeding events were six with 150 mg bid AZD0837, 15 with 350 mg bid AZD0837 and eight with warfarin. Alanine aminotransferase elevations (> 3 x upper limit of normal) were infrequent, without apparent differences between treatment groups. A numerically higher incidence of serious adverse events was observed with 350 mg bid AZD0837 compared with 150 mg bid, with six of 13 being cardiac related, all with different diagnoses. An increase in mean serum creatinine of approximately 10% was observed in both AZD0837 groups, which returned to baseline after completion of therapy. There were no strokes, transient ischaemic attacks or cerebral haemorrhages with any of the treatments. In conclusion, the safety and tolerability of 150 mg bid immediate-release AZD0837 appeared to be as good as that of dose-adjusted warfarin. However, larger studies will be needed to define the safety profile of AZD0837.

Keywords

Stroke - atrial fibrillation - anticoagulant - oral direct thrombin inhibitor - AZD0837

Volltext

Referenzen

References
1 Singer DE, Albers GW, Dalen JE. et al. Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133: 546S-592S.
2 Fuster V, Ryden LE, Cannom DS. et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: full text: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to revise the 2001 guidelines for the management of patients with atrial fibrillation) developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Europace 2006; 8: 651-745.
3 Braunwald E. Shattuck lecture--cardiovascular medicine at the turn of the millennium: triumphs, concerns, and opportunities. N Engl J Med 1997; 337: 1360-1369.
4 Chugh SS, Blackshear JL, Shen WK. et al. Epidemiology and natural history of atrial fibrillation: clinical implications. J Am Coll Cardiol 2001; 37: 371-378.
5 Ansell J, Hirsh J, Hylek E. et al. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133: 160S-198S.
6 Hughes M, Lip GY. Stroke and thromboembolism in atrial fibrillation: a systematic review of stroke risk factors, risk stratification schema and cost effectiveness data. Thromb Haemost 2008; 99: 295-304.
7 Palareti G, Cosmi B. Bleeding with anticoagulation therapy – who is at risk, and how best to identify such patients. Thromb Haemost 2009; 102: 268-278.
8 Wysowski DK, Nourjah P, Swartz L. Bleeding complications with warfarin use: a prevalent adverse effect resulting in regulatory action. Arch Intern Med 2007; 167: 1414-1419.
9 Weitz JI, Hirsh J, Samama MM. New antithrombotic drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133: 234S-256S.
10 Weitz JI. Factor Xa or thrombin: is thrombin a better target?. J Thromb Haemost 2007; 5: 65.
11 Nieuwlaat R, Capucci A, Camm AJ. et al. Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation. Eur Heart J 2005; 26: 2422-2434.
12 Nieuwlaat R, Olsson SB, Lip GY. et al. Guideline-adherent antithrombotic treatment is associated with improved outcomes compared with undertreatment in high-risk patients with atrial fibrillation. The Euro Heart Survey on Atrial Fibrillation. Am Heart J 2007; 153: 1006-1012.
13 Connolly SJ, Pogue J, Eikelboom J. et al. Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. Circulation 2008; 118: 2029-2037.
14 Deinum J, Mattsson C, Inghardt T. et al. Biochemical and pharmacological effects of the direct thrombin inhibitor AR-H067637. Thromb Haemost 2009; 101: 1051-1059.
15 Gyzander E, Deinum J. Enzyme kinetic characterisation of the active form of the novel oral direct thrombin inhibitor AZD0837. J Thromb Haemost. 2007 5: Abstract P-S-066.
16 Gustafsson D, Bylund R, Antonsson T. et al. A new oral anticoagulant: the 50-year challenge. Nat Rev Drug Discov 2004; 3: 649-659.
17 Sanford M, Plosker GL. Dabigatran etexilate. Drugs 2008; 68: 1699-1709.
18 Cullberg M, Wåhlander K, Jansson SO. et al. Safety, pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor AZD0837 in young healthy volunteers. Basic Clin Pharmacol Toxicol 2007; 101: 130 (Abstract 206).
19 Lee WM, Larrey D, Olsson R. et al. Hepatic findings in long-term clinical trials of ximelagatran. Drug Saf 2005; 28: 351-370.
20 Lip GYH, Rasmussen LH, Olsson SB. et al. Oral direct thrombin inhibitor AZD0837 for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: a randomised dose-guiding, safety and tolerability study of four doses of AZD0837 versus vitamin K antagonists. Eur Heart J 2009; 30: 2897-2907.
21 Ezekowitz MD, Reilly PA, Nehmiz G. et al. Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study). Am J Cardiol 2007; 100: 1419-1426.
22 Connolly SJ, Ezekowitz MD, Yusuf S. et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-1151.
23 Walfridsson H, Johansson B, Englund A. et al. Assessment of the electrophysiological effects of the oral direct thrombin inhibitor AZD0837, in subjects undergoing an invasive electrophysiological procedure. J Thromb Haemost. 2007 5: Abstract P-W-674.
24 Schützer K, Svensson M, Dellstrand M. et al. Effect of the oral direct thrombin inhibitor AZD0837 on glomerular filtration rate in elderly healthy subjects. J Thromb Haemost. 2007 5: Abstract P-W-668.